Clinical prevention of recurrence of colorectal adenomas by the combination of difluoromethylornithine and sulindac: An important milestone

Cancer Prevention Research

Volumn 1, Issue 1, 2008, Pages 9-11

  Sporn, Michael B ^a   Hong, Waun Ki ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EFLORNITHINE; SULINDAC;

ADENOMA; CLINICAL TRIAL; COLORECTAL TUMOR; HUMAN; NOTE; PATHOLOGY; TUMOR RECURRENCE;

ADENOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; EFLORNITHINE; HUMANS; NEOPLASM RECURRENCE, LOCAL; SULINDAC;

EID: 55549127613     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0049     Document Type: Review

References (22)

1. Meyskens FL, McLaren CE, Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res 2008;1. In press.
2. Sporn MB. Combination chemoprevention of cancer. Nature 1980;287:107-8.
3. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997;278: 1073-7.
4. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90.
5. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
6. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-95.
7. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355: 873-84.
8. Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006;131: 1674-82.
9. Meyskens FL, Jr., Emerson SS, Pelot D, et al. Dose de-escalation chemoprevention trial of α-difluoromethylornithine in patients with colon polyps. J Natl Cancer Inst 1994;86:1122-30.
10. Meyskens FL, Jr., Gerner EW, Emerson S, et al. Effect of α-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, doubleblinded trial for colon cancer prevention. J Natl Cancer Inst 1998;90:1212-8.
11. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-6.
12. Gerner EW, Meyskens FL, Jr. Polyamines and cancer: old molecules, newunder standing. Nat Rev Cancer 2004;4:781-92.
13. Pegg AE, Feith DJ. Polyamines and neoplastic growth. Biochem Soc Trans 2007;35:295-9.
14. Piazza GA, Alberts DS, Hixson LJ, et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997;57: 2909-15.
15. Thompson WJ, Piazza GA, Li H, et al. Exisulind induction of apoptosis involves guanosine 3″,5″-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated β-catenin. Cancer Res 2000;60:3338-42.
16. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
17. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
18. Loveridge CJ, Macdonald AD, Thoms HC, Dunlop MG, Stark LA. The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA (p65) subunit of NF-κB. Oncogene 2007. In press.
19. Mahmoud NN, Boolbol SK, Dannenberg AJ, et al. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis 1998;19:87-91.
20. Nigro ND, Bull AW, Boyd ME. Inhibition of intestinal carcinogenesis in rats: effect of difluoromethylornithine with piroxicam or fish oil. J Natl Cancer Inst 1986;77:1309-13.
21. Rao CV, Tokumo K, Rigotty J, Zang E, Kelloff G, Reddy BS. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, α-difluoromethylornithine, 16α-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res 1991;51: 4528-34.
22. Sporn MB. Dichotomies in cancer research: some suggestions for a newsynthes is. Nat Clin Pract Oncol 2006;3:364-73.